(Reuters Health)—A once-daily 15 mg dose of upadacitinib for rheumatoid arthritis (RA) has similar rates of malignancies, serious infections, major adverse cardiovascular events, and venous thromboembolic events as other Janus kinase inhibitors (jakinibs), results from phase 3 clinical trials suggest. Researchers examined data on treatment emergent adverse events among patients taking upadacitinib in five randomized…
Articles by Natasha Yetman
We Are Rheumatology: Rheumatology Must Continue to Overcome the Challenges of the Pandemic
Vaneet K Sandhu, MD, FACR, RhMSUS, discusses how rheumatologists should persevere and collaborate with colleagues to overcome the challenges of the pandemic.
Adapting Care During COVID-19: Q&A with Brett Smith, DO
The COVID-19 global pandemic has disrupted rheumatology clinics and practices all over the world. In the U.S., many providers have used telemedicine to expand access to care for their patients while managing in-person visits. Brett Smith, DO, who practices at the Blount Memorial Physicians Group, East Tennessee Children’s Hospital, Knoxville, spoke with The Rheumatologist about…
Staying Positive & Learning from COVID-19: Q&A with Nilanjana Bose, MD, MBA
Pandemic fatigue is affecting rheumatologists and their patients in different ways, says Nilanjana Bose, MD, MBA. But efforts are being made at her clinic to stay positive and ensure quality patient care.
Ultrasound Provides Insights into Immune Checkpoint Inhibitor‐Induced Inflammatory Arthritis
Ultrasound may provide unique insights into the effects of immune checkpoint inhibitors on the human body beyond the immune system. Research suggests synovitis and inflammatory tendon involvement are commonly seen in patients with immune checkpoint inhibitor-induced inflammatory arthritis.
Janus Kinase vs. TNF Inhibitors: The Context for Venous Thromboembolism Risk with RA Treatments
An observational study found treatment with tofacitinib resulted in only a slightly higher rate of venous thromboembolism than tumor necrosis factor inhibitors in patients with rheumatoid arthritis.
Oxford University to Study Adalimumab as Potential COVID-19 Treatment
LONDON (Reuters)—Oxford University said on Wednesday it will study whether the prescription medicine, adalimumab (Humira), is an effective treatment for COVID-19 patients—the latest effort to repurpose existing drugs as potential coronavirus therapies. Adalimumab, which is sold by AbbVie, is a type of anti-inflammatory known as an anti-tumour necrosis factor (anti-TNF) drug. Recent studies have shown…
Arthroscopic Partial Meniscectomy Tied to Radiographic Knee OA
(Reuters Health)—Patients with a degenerative meniscus tear who get arthroscopic partial meniscectomy have similar five-year outcomes and increased risk of radiographic knee osteoarthritis (OA) as without surgery, a small study suggests. Researchers in Finland randomly assigned 146 adults with degenerative meniscus tear confirmed by magnetic resonance imaging (MRI) to receive either arthroscopic partial meniscectomy (APM)…
Monthly Belimumab Infusions Preserve Kidney Function in Some Lupus Patients
(Reuters Health)—Intravenous belimumab combined with standard lupus therapy can help preserve kidney function in patients with active lupus nephritis and cut the odds of death or a renal-related event by half, a phase 3 multinational study has concluded.1 After two years of therapy, 43% of 224 volunteers getting the drug monthly showed a renal response…
Polymyalgia Rheumatica Rapid Symptom Improvement After Glucose Is Controlled
(Reuters Health)—In a case series report, researchers describe rapid symptom improvement in three patients with polymyalgia rheumatica (PMR) when high glucose levels were brought down. After glucose was controlled, patients experienced improvement in both symptoms and laboratory measures of PMR without glucocorticoid administration or an increase in glucocorticoid dosage, according to the report in the…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 97
- Next Page »